This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MaxCyte’s 8K filing here.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
- Five stocks we like better than MaxCyte
- What Are the FAANG Stocks and Are They Good Investments?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Use High Beta Stocks to Maximize Your Investing Profits
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 01/13 – 01/17
